Search Result

Results for "

somatostatin receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Somatostatin Receptor (83) Adenylate Cyclase (2) Amylin Receptor (1) Amyloid-β (1) Apoptosis (7) Bombesin Receptor (3) CRFR (2) Dopamine Receptor (2) Drug Derivative (2) Endogenous Metabolite (1) Isotope-Labeled Compounds (4) Liposome (4) Opioid Receptor (2) PACAP Receptor (1) Radionuclide-Drug Conjugates (RDCs) (9) Reference Standards (2) Urotensin Receptor (2)
By Research Areas:	Cancer (41) Cardiovascular Disease (18) Endocrinology (31) Inflammation/Immunology (16) Metabolic Disease (18) Neurological Disease (37)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Pegylated Lipids (4)

101

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Protéines recombinantes

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Octreotide Maximum Cited Publications 16 Publications Verification SMS 201-995	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the **somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

Pasireotide 5+ Cited Publications SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

DOTAMTATE	Drug Derivative	Cancer
DOTAMTATE is a somatostatin analogue. DOTAMTATE marked ²¹²Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .

CTAP 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

Calcitonin (8-32), salmon	Amylin Receptor	Metabolic Disease
Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

DOTA-LM3 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective **somatostatin sst2 receptor antagonist, with pIC₅₀** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a **somatostatin receptor 2 （SSTR2**）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective **somatostatin receptor type 4 (SST4 receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST4 receptors*, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

Pasireotide acetate 2 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

Mazisotine LY3556050; CNTX-0290	Somatostatin Receptor	Neurological Disease
Mazisotine (CNTX-0290) is an orally active, non-opioid somatostatin receptor 4 (SSTR4) agonist with an EC₅₀ of 4.7 nM. Mazisotine exerts significant analgesic effects in various nociceptive (inflammatory, osteoarthritic) and neuropathic pain models. Mazisotine can be used for pain research .

Cyclosomatostatin 1 Publications Verification	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

L-803087	Somatostatin Receptor	Neurological Disease Cancer
L-803087 is a potent and selective **somatostatin sst4 receptor agonist with a K_i** of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

DOTA-LM3 TFA 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

SSTR5 antagonist 1	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC₅₀s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .

CH 275 1 Publications Verification	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of **somatostatin receptor** subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

SRA880	Somatostatin Receptor	Cardiovascular Disease
SRA880 is a non-peptide and selective **somatostatin sst(1) receptor** antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC₅₀ value of 1.3 nM against sst2 when labeled with [ ¹¹¹In-DTPA], and an IC₅₀ value of 1.6 nM against sst2 when labeled with [ ⁹⁰Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with ¹⁷⁷Lu or ⁹⁰Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .

PRL 2915 1 Publications Verification	Somatostatin Receptor Urotensin Receptor	Endocrinology
PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM .

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive **Somatostatin receptor antagonist, with pA2** values of 6.50, 6.24 and 6.09 against SS₁₄, SS₂₅ and SS₂₈, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus .

Pasireotide ditrifluoroacetate 5+ Cited Publications SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .

Pasireotide L-aspartate salt 5+ Cited Publications SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and *selective somatostatin* (receptor) subtype 5 (SSTR5)** antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

L-817818	Somatostatin Receptor	Endocrinology
L-817818 is a potent and subtype-selective agonist of the **somatostatin receptor*. L-817818 provides a direct approach to defining somatostatin* receptor physiological functions

CTAP TFA 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

Alkyne-βAG-TOCA	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

NNC 26-9100	Somatostatin Receptor Amyloid-β	Neurological Disease
NNC 26-9100 is a selective somatostatin sst4 receptor full agonist (K_i: 6 nM, EC₅₀: 2 nM). NNC 26-9100 decreases total soluble Aβ42, increases brain neprilysin activity and improves learning .

MMC(TMZ)-TOC TFA	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC TFA has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC TFA targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC TFA can be used for the research of cancer .

SSTR4 agonist 2	Somatostatin Receptor	Inflammation/Immunology
SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107) .

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

Octreotide dihydrochloride SMS 201-995 dihydrochloride	Somatostatin Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) hydrochloride is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the **somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

SSTR4 agonist 4	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 4 is a somatostatin receptor 4 (SSTR4) agonist. SSTR4 agonist 4 functionally activates SSTR4. SSTR4 agonist 4 has the potential for the research of pain .

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

Pentetreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with ¹¹¹In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

L-796778	Somatostatin Receptor	Others
L-796778 is an agonist of the hsst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 is a partial agonist that inhibits forskolin (HY-15371)-stimulated cAMP production with an IC₅₀ value of 18 nM .

Cat. No.	Nom du produit	Type

HY-172280A

DSPE-PEG2000-octreotide	Biochemical Assay Reagents
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .

HY-172280C

DSPE-PEG3400-octreotide	Biochemical Assay Reagents
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .

HY-172280B

DSPE-PEG5000-octreotide	Biochemical Assay Reagents
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .

HY-172280

DSPE-PEG1000-octreotide	Biochemical Assay Reagents
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .

Cat. No.	Nom du produit	Target	Research Area

HY-P0036

Octreotide Maximum Cited Publications 16 Publications Verification SMS 201-995	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the **somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-16381

Pasireotide 5+ Cited Publications SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P10920

DOTAMTATE	Drug Derivative	Cancer
DOTAMTATE is a somatostatin analogue. DOTAMTATE marked ²¹²Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .

HY-P1335

CTAP 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1782

Calcitonin (8-32), salmon	Amylin Receptor	Metabolic Disease
Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P5126

DOTA-LM3 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective **somatostatin sst2 receptor antagonist, with pIC₅₀** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a **somatostatin receptor 2 （SSTR2**）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-111615

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective **somatostatin receptor type 4 (SST4 receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST4 receptors*, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-16381A

Pasireotide acetate 2 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1201

Cyclosomatostatin 1 Publications Verification	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P5126A

DOTA-LM3 TFA 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P1206

CH 275 1 Publications Verification	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of **somatostatin receptor** subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC₅₀ value of 1.3 nM against sst2 when labeled with [ ¹¹¹In-DTPA], and an IC₅₀ value of 1.6 nM against sst2 when labeled with [ ⁹⁰Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with ¹⁷⁷Lu or ⁹⁰Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .

HY-P4452

PRL 2915 1 Publications Verification	Somatostatin Receptor Urotensin Receptor	Endocrinology
PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive **Somatostatin receptor antagonist, with pA2** values of 6.50, 6.24 and 6.09 against SS₁₄, SS₂₅ and SS₂₈, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus .

HY-79136

Pasireotide L-aspartate salt 5+ Cited Publications SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-P1335A

CTAP TFA 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

HY-P10758

Alkyne-βAG-TOCA	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-P0036A

Octreotide dihydrochloride SMS 201-995 dihydrochloride	Somatostatin Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) hydrochloride is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the **somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P2022

Pentetreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with ¹¹¹In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .

HY-P0024A

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P1207

BIM 23052	Somatostatin Receptor	Neurological Disease
BIM 23052 is a somatostatin receptor 5 agonist. BIM 23052 can induce gastric emptying .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a **somatostatin receptor antagonist with K_i*s of 6, 17, 66, 1000 and 1000 nM for human somatostatin* receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared withOctreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-108768

Pasireotide pamoate 5+ Cited Publications SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-P3618

Cortistatin-29 (reduced)	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all **somatostatin (SS) receptor subtypes with high affinity and shows IC₅₀** values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .

HY-P0036B

Octreotide pamoate SMS 201-995 pamoate	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) pamoate is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the **somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

HY-P3958

BIM-23027	Somatostatin Receptor Dopamine Receptor	Neurological Disease
BIM-23027 is a selective agonist of sst₂ receptor (EC₅₀=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P4957

Octreotide dimer (parallel)	Somatostatin Receptor	Others
Octreotide dimer parallel is a dimer parallel of Octreotide. Octreotide (HY-P0036) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P4100

Cyclic SSTR agonist octreotide	Somatostatin Receptor	Others
Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic **Somatostatin Receptor SSTR** agonist .

Recombinant Proteins Recommended:

Somatostatin Receptor

Species:	Human (3)
Tag:	GFP (1) His (1) Tag Free (1)
Source:	HEK293 (3)

Cat. No.	Compare	Nom du produit	Species	Source	Image

HY-P704897

	SSTR2 Protein-VLP, Human (HEK293) SSTR2; somatostatin receptor 2; somatostatin receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
	SSTR2 Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

HY-P700430

	SSTR2 Protein-VLP, Human (HEK293, His) SSTR2; somatostatin receptor 2; somatostatin receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
	SSTR2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA, FACS. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P704898

	SSTR2 Protein-VLP, Human (HEK293, GFP) SSTR2; somatostatin receptor 2; somatostatin receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
	SSTR2 Protein-VLP, Human (HEK293, GFP) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Ajouter au chariot Obtenir un devis

Cat. No.	Nom du produit	Chemical Structure

HY-P0036S4

Octreotide-d8 acetate

Octreotide-d₈ (acetate) (SMS 201-995-d₈ (acetate)) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P0036S2

Octreotide-d8

Octreotide-d₈ (SMS 201-995-d₈) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P0036S3

Octreotide-13C9,15N

Octreotide- ¹³C₉, ¹⁵N (SMS 201-995- ¹³C₉, ¹⁵N) is ¹³C and ¹⁵N labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P0036S

Octreotide-d8 TFA

Octreotide-d₈ (SMS 201-995-d₈) TFA is the deuterium labeled Octreotide TFA. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.

Host:	Mouse (2) Rabbit (6)
Reactivity:	Human (8) Rat (1) Mouse (1)
Application:	IHC-P (2) ICC/IF (1) WB (4) FC (3) ELISA (2)
Isotype:	IgG (6) IgG1 (2)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (4) Recombinant (4)
Modification:	Unmodified (5)

Cat. No.	Compare	Nom du produit	Application	Reactivity	Image

HY-P84249

	Somatostatin Receptor 2 Antibody (YA3946)	FC, ELISA	Human
	Somatostatin Receptor 2 Antibody (YA3946) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P87450

	Somatostatin Receptor 1 Antibody (YA7137)	WB, ICC/IF	Human
	Somatostatin Receptor 1 Antibody (YA7137) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 1.

HY-P81452

	Somatostatin Receptor 2 Antibody (YA1197) SSTR2; somatostatin receptor 2; SS 2 R; SS2R; SRIF 1; SS2 R	IHC-P	Human
	Somatostatin Receptor 2 Antibody (YA1197) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P81452A

	Somatostatin Receptor 2 Antibody (YA1197)(PBS only) SSTR2; somatostatin receptor 2; SS 2 R; SS2R; SRIF 1; SS2 R	IHC-P	Human
	Somatostatin Receptor 2 Antibody (YA1197) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P84249A

	Somatostatin Receptor 2 Antibody (YA3946)(PBS only) somatostatin receptor type 2, SS-2-R, SS2-R, SS2R, SST2, SRIF-1, SSTR2	FC, ELISA	Human
	Somatostatin Receptor 2 Antibody (YA3946) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P83055

	Somatostatin Receptor 5 Antibody (YA2800) SSTR5; SS5R; Sstr5	WB, FC	Human, Mouse, Rat
	Somatostatin Receptor 5 Antibody (YA2800) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 5.

HY-P82287

	Somatostatin Receptor 3 Antibody (YA2032) SS3R; SS3-R; SS-3-R; SSR-28	WB	Human
	Somatostatin Receptor 3 Antibody (YA2032) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 3.

HY-P82287A

	Somatostatin Receptor 3 Antibody (YA2032)(PBS only) SS3R; SS3-R; SS-3-R; SSR-28	WB	Human
	Somatostatin Receptor 3 Antibody (YA2032) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 3.